This study is being done in adults with Systemic Lupus Erythematosus, a long-term disease in which the immune system attacks the body’s own tissues. The treatment being tested is nipocalimab, given as an injection under the skin, compared with placebo. The purpose of the study is to see whether nipocalimab can reduce disease activity in people with this condition.
The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.
1start of the study
After joining the study, you are placed into one of two treatment groups by chance. The study is randomized, which means the treatment assignment is made by a random process.
The study is double-blind, which means that neither you nor the study team will know whether you are receiving nipocalimab or placebo during the study.
The study is placebo-controlled, which means one group receives placebo, a study treatment that does not contain nipocalimab.
2study treatment period
You receive either nipocalimab or placebo as a subcutaneous injection, which means an injection given under the skin.
Nipocalimab is given as a solution for injection. The listed dose is 0 in the source data, and no dosing frequency or treatment duration is specified in the source data.
The placebo is given by the same subcutaneous route. No dose, frequency, or treatment duration is specified in the source data.
You continue in the study while the treatment period is carried out according to the study plan.
3assessment of treatment effect
Your disease activity is checked during the study to see how well the treatment is working.
The main study result is measured at week 52 using the sri-4 result, which stands for systemic lupus erythematosus responder index-4. This is a combined measure used to show whether your lupus disease activity has improved.
4end of the study
The study continues until the planned end of the trial period.
The estimated study end date is 2031-02-21.
Who Can Join the Study?
Adult at the time of signing the informed consent form, meaning the person must be legally an adult when agreeing to join the study.
Have a diagnosis of systemic lupus erythematosus (SLE).
Have at least 1 positive autoantibody, meaning a blood test must show at least one antibody that reacts against the body’s own tissues.
Have a SLEDAI-2K score available, which is a doctor-used score that measures how active the lupus is.
Have a BILAG score available, which is another doctor-used score that checks how active the disease is in different body systems.
Who Cannot Join the Study?
Any condition that the study doctor thinks would make participation not in the patient’s best interest.
Any clinically significant laboratory abnormality, meaning an important abnormal result in blood, urine, or other lab tests that is not considered suitable for the study.
Comorbidities that require systemic glucocorticoids (GCs), meaning another medical condition that needs steroid medicine taken by mouth, by injection, or in a way that affects the whole body.
Inflammatory diseases, meaning other conditions that cause ongoing swelling, redness, or irritation in the body.
A major surgical procedure before screening, meaning a large operation done before the study checks whether the person can join.
nipocalimab is the study medicine being tested in this trial. It is given as an injection under the skin. The goal of the study is to see whether it can help lower disease activity in adults with moderate to severe systemic lupus erythematosus, which is an autoimmune disease where the immune system attacks the body’s own tissues.
Systemic Lupus Erythematosus – Systemic lupus erythematosus is a long-term autoimmune disease in which the immune system mistakenly attacks healthy tissues. It can affect the skin, joints, kidneys, blood, and other organs. The illness often develops in periods of flare and remission, with symptoms that may come and go over time. Its course can vary widely from mild to more widespread disease, and new organs may become involved as it progresses.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Czechia 
Denmark 
Finland 
France 
Germany 
Greece 
Hungary 
Italy 
Norway 
Poland 
Portugal 
Romania 
Slovakia 
Spain 